Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONC

<< Previous

Bullboard Posts

Next >>

Comment by Capitalistaon Jun 28, 2023 11:46am

164 Views

Post# 35518607

RE:RE:RE:RE:RE:RE:RE:ONC

Specious? I think not. Can you justify that comment? Or, in your own words, "post your proof".

I'm not the one selling either, if that's what you're implying.

And to reply to your earlier comment - of course this is 2023, not 2022. I'm simply offering one possible explanation of why the share price is not rising to what we all think the company is worth. (Well, most of us).

ONC has a cash runway for a year at least, but not if they plan to engage in two Phase III programs. Raising more money is crucial at this point. My hope is that a partnership/buyout occurs soon so we can stop this slow bleed.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec